Streetbeat News

Regulatory

SPY

The S&P Global Composite PMI for September was reported at 50.2, which is in line with the prior figure and slightly above the estimate of 50.1.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:45 pm

AEHL

Antelope Enterprise Holdings Limited (AEHL), which operates KylinCloud, a livestreaming ecommerce business in China, has regained compliance with NASDAQ's minimum bid price requirement under Listing Rule 5550(a)(2). The company's Class A ordinary shares were at or above $1.00 for 10 consecutive business days.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:36 pm

MRNA

NVAX

Moderna, Inc (NASDAQ:MRNA) shares are trading higher after the company announced positive interim results from its Phase 1/2 trial of mRNA-1083, a combination vaccine against influenza and Covid-19. The vaccine has been selected to advance to Phase 3 trials, with regulatory approval targeted for 2025. Shares of competitor Novavax Inc (NASDAQ:NVAX) also surged after the FDA granted Emergency Use Authorization for its updated Covid-19 vaccine.

Portfolio Pulse from Adam Eckert

October 04, 2023 | 1:27 pm

HLTH

Cue Health's molecular COVID-19 test has been found to be as accurate as a lab-based PCR test, according to a peer-reviewed independent study published in Microbiology Spectrum. The study found that Cue's test had a 99.4% match with lab-based PCR tests and 100% clinical sensitivity to detect positive cases. Cue Health recently received De Novo authorization from the FDA for its COVID-19 test.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:21 pm

FTTUSD

The U.S. Department of Justice (DOJ) has stated that existing laws are sufficient to charge FTX founder Sam Bankman-Fried for his alleged involvement in fraudulent activities. The DOJ believes that the evidence against Bankman-Fried, particularly concerning the misappropriation of customer funds and their use in political campaigns, is clear and compelling. The DOJ also emphasized that compliance with other regulations or laws does not serve as evidence of good faith.

Portfolio Pulse from Murtuza Merchant

October 04, 2023 | 1:07 pm

PTPI

Petros Pharmaceuticals has announced the completion of a label comprehension study for a potential over-the-counter (OTC) label for STENDRA. This is a significant step towards making STENDRA available as an OTC product.

Portfolio Pulse from Bill Haddad

October 04, 2023 | 1:07 pm

NTRA

Natera, Inc. (NASDAQ:NTRA) has announced a new study published in Frontiers in Oncology demonstrating the ability of its molecular residual disease (MRD) test, Signatera, to detect early progression and risk stratify patients with unresectable stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiotherapy. The study showed 82% pre-treatment detection, with 100% longitudinal sensitivity and specificity to disease progression. The study builds on previous data supporting the use of Signatera to detect progression early in resected, early-stage NSCLC patients.

Portfolio Pulse from Benzinga Newsdesk

October 04, 2023 | 1:06 pm

AAPL

AYI

BTCUSD

DWAC

ETHUSD

NVAX

PLTR

RPM

SPY

TSLA

The article covers a range of topics including the fall of cryptocurrencies like Bitcoin, Ethereum, and Dogecoin due to recession worries, the uncertainty in US politics following the removal of Kevin McCarthy as House Speaker, and the performance of various stocks including RPM International, Acuity Brands, Digital World, Novavax, Palantir, and Tesla. It also discusses the surge in Ripple's XRP token, the potential spike in 10-year Treasury yield, and the performance of real estate stocks. In the tech sector, Apple's stock downgrade and potential layoffs at Meta are highlighted. The article also mentions the EV sector, with Tesla's new upgrades and Volkswagen's efforts to tackle EV software challenges.

Portfolio Pulse from Akanksha Bakshi

October 04, 2023 | 12:54 pm

AAPL

Apple Inc. has complied with the Chinese government's new rules for app stores, requiring developers to obtain a government license before submitting new apps to the App Store. The Chinese market contributes 19% to Apple's top line, making it crucial for the company to adhere to these regulations. This is not the first time Apple has had to adjust its operations to comply with Chinese regulations, having previously removed thousands of apps from the App Store in China.

Portfolio Pulse from Rounak Jain

October 04, 2023 | 12:45 pm

FRLN

IKT

PLTR

Freeline reported positive initial clinical data from the first cohort of its Phase 1/2 GALILEO-1 trial of FLT201, a novel gene therapy candidate for Gaucher Disease. Inhibikase Therapeutics received FDA Orphan Drug Designation for Risvodetinib for the treatment of Multiple System Atrophy. Palantir Technologies collaborated with PwC to accelerate operational transformation.

Portfolio Pulse from ryanfaloona@benzinga.com

October 04, 2023 | 12:43 pm